Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapcabtagene Autoleucel Versus Rituximab in Severe Refractory Diffuse Cutaneous Systemic Sclerosis
NCT06655896Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2024
- Primary completion
- Nov 2028
- Countries
- 22
01
Overview
A Phase 2 trial of rapcabtagene autoleucel in diffuse cutaneous systemic sclerosis (dcSSc), sponsored by Novartis. Started Oct 2024; status: active, not recruiting.
02
Drugs
rapcabtagene autoleucel
03
Conditions
diffuse cutaneous systemic sclerosis (dcSSc)
Beyond the preview
Go deeper on NCT06655896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06655896.